 GlaxoSmithKline plc NYSE: GSK, Pfizer Inc NYSE: PFE, and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc NASDAQ: HALO to gain access to Halozymes Enhanze drug delivery technology for use against four HIV targets. ViiV Healthcare will pay 40 million upfront and up to 175 million in milestones, as well as mid-single-digit royalties on future sales. 